Gene Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Gene Biotherapeutics's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2020 |
Recent past performance updates
No updates
Recent updates
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Gene Biotherapeutics has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
Show sectionRevenue & Expenses BreakdownBeta
How Gene Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | 1 | 1 | 0 |
| 30 Jun 20 | 0 | 2 | 1 | 0 |
| 31 Mar 20 | 0 | 1 | 1 | 0 |
| 31 Dec 19 | 0 | 1 | 1 | 0 |
| 31 Dec 18 | 0 | 0 | 1 | 0 |
| 31 Dec 17 | 0 | -2 | 2 | 0 |
| 31 Mar 17 | 0 | -4 | 2 | 1 |
| 31 Dec 16 | 0 | -4 | 2 | 1 |
| 30 Sep 16 | 0 | -3 | 2 | 0 |
| 30 Jun 16 | 0 | -3 | 2 | 0 |
| 31 Mar 16 | 0 | -4 | 3 | 0 |
| 31 Dec 15 | 0 | -4 | 3 | 0 |
| 30 Sep 15 | 0 | -6 | 3 | 1 |
| 30 Jun 15 | 0 | -5 | 2 | 1 |
| 31 Mar 15 | 0 | -5 | 2 | 0 |
| 31 Dec 14 | 0 | -6 | 3 | 1 |
| 30 Sep 14 | 0 | -5 | 4 | 1 |
| 30 Jun 14 | 0 | -6 | 4 | 1 |
| 31 Mar 14 | 0 | -7 | 5 | 2 |
| 31 Dec 13 | 0 | -7 | 5 | 2 |
| 30 Sep 13 | 0 | -8 | 5 | 2 |
| 30 Jun 13 | 0 | -8 | 5 | 2 |
Quality Earnings: Insufficient data to determine if CRXM has high quality earnings.
Growing Profit Margin: Insufficient data to determine if CRXM's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CRXM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare CRXM's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if CRXM's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: CRXM has a negative Return on Equity (0%), as it is currently unprofitable.